|
121 |
Design and baseline characteristics of participants in the Researching cardiovascular Events with a Weekly INcretin in Diabetes (REWIND) trial on the cardiovascular effects of dulaglutide |
Gerstein HC, Colhoun HM, Dagenais GR, Diaz R, Lakshmanan M, Pais P, Probstfield J, Riddle MC, Rydén L, Xavier D, Atisso CM, Avezum A, Basile J, Chung N, Conget I, Cushman WC, Franek E, Hancu N, Hanefeld M, Holt S, Jansky P, Keltai M, Lanas F, Leiter LA, Lopez-Jaramillo P, Cardona-Munoz EG, Pirags V, Pogosova N, Raubenheimer PJ, Shaw J, Sheu WH, Temelkova-Kurktschiev T; REWIND Trial Investigators. |
Diabetes Obes Metab |
2018 |
|
122 |
Predictors, Prognosis, and Management of New Clinically Important Atrial Fibrillation After Noncardiac Surgery: A Prospective Cohort Study |
Alonso-Coello P, Cook D, Xu SC, Sigamani A, Berwanger O, Sivakumaran S, Yang H, Xavier D, Martinez LX, Ibarra P, Rao-Melacini P, Pogue J, Zarnke K, Paniagua P, Ostrander J, Yusuf S, Devereaux PJ; POISE Investigators |
Anesth Analg |
2017 |
|
123 |
Home Blood Pressure Management Intervention in Low- to Middle-Income Countries: Protocol for a Mixed Methods Study |
Anderson C, Dadabhai S, Damasceno A, Dzudie A, Islam SMS, Kamath D, Kandula N, Kayange N, Quispe R, Roy A, Shah S, Vidal-Perez R |
JMIR Res Protoc |
2017 |
|
124 |
Regional differences in presentation and antithrombotic treatment of patients with atrial fibrillation: Baseline characteristics from a clustered randomized trial to IMProve treatment with AntiCoagulanTs in patients with atrial fibrillation (IMPACT-AF) |
Vinereanu D, Al-Khalidi HR, Rao MP, He W, Lopes RD, Bahit CM, Ciobanu AO, Fox KA, Pokorney SD, Xian Y, Jiang J, Kamath DY, Berwanger O, Tajer C, Huo Y, Xavier D, Granger CB |
Am Heart J |
2017 |
|
125 |
Antiinflammatory Therapy with Canakinumab for Atherosclerotic Disease |
Ridker PM, Everett BM, Thuren T, MacFadyen JG, Chang WH, Ballantyne C, Fonseca F, Nicolau J, Koenig W, Anker SD, Kastelein JJP, Cornel JH, Pais P, Pella D, Genest J, Cifkova R, Lorenzatti A, Forster T, Kobalava Z, Vida-Simiti L, Flather M, Shimokawa H, Ogawa H, Dellborg M, Rossi PRF, Troquay RPT, Libby P, Glynn RJ; CANTOS Trial Group. |
N Engl J Med |
2017 |
|
126 |
A multifaceted intervention to improve treatment with oral anticoagulants in atrial fibrillation (IMPACT-AF): an international, cluster-randomised trial |
Vinereanu D, Lopes RD, Bahit MC, Xavier D, Jiang J, Al-Khalidi HR, He W, Xian Y, Ciobanu AO, Kamath DY, Fox KA, Rao MP, Pokorney SD, Berwanger O, Tajer C, de Barros E Silva PGM, Roettig ML, Huo Y, Granger CB; IMPACT-AF investigators. |
Lancet |
2017 |
|
127 |
Association of Postoperative High-Sensitivity Troponin Levels With Myocardial Injury and 30-Day Mortality Among Patients Undergoing Noncardiac Surgery |
Writing Committee for the VISION Study Investigators, Devereaux PJ, Biccard BM, Sigamani A, Xavier D, Chan MTV, Srinathan SK, Walsh M, Abraham V, Pearse R, Wang CY, Sessler DI, Kurz A, Szczeklik W, Berwanger O, Villar JC, Malaga G, Garg AX, Chow CK, Ackland G, Patel A, Borges FK, Belley-Cote EP, Duceppe E, Spence J, Tandon V, Williams C, Sapsford RJ, Polanczyk CA, Tiboni M, Alonso-Coello P, Faruqui A, et al. |
JAMA |
2017 |
|
128 |
The World Heart Federation Roadmap for Nonvalvular Atrial Fibrillation |
Murphy A, Banerjee A, Breithardt G, Camm AJ, Commerford P, Freedman B, Gonzalez-Hermosillo JA, Halperin JL, Lau CP, Perel P, Xavier D, Wood D, Jouven X, Morillo CA |
Glob Heart |
2017 |
|
129 |
Uses of polypills for cardiovascular disease and evidence to date |
Huffman MD, Xavier D, Perel P |
Lancet |
2017 |
|
130 |
Nations within a nation: variations in epidemiological transition across the states of India, 1990-2016 in the Global Burden of Disease Study |
Kurpad A, Xavier, D, et al; India State-Level Disease Burden Initiative Collaborators |
Lancet |
2017 |
|
131 |
Use of interacting drugs did not modify treatment effects of apixaban versus warfarin for atrial fibrillation: results from the Aristotle trial
|
Jeffrey B. Washam, Stefan Hohnloser, Daniel Wojdyla, Elaine M,Hylek, Steen Husted, *Denis Xavier*, Duke Clinical Research Institute, Duke University School of Medicine, Durham, NC USA, et al.
|
Journal of the American College of Cardiology |
2017 |
|
132 |
Cholesterol Lowering in Intermediate-Risk Persons without Cardiovascular Disease |
Yusuf S, Bosch J.,Dagenais G, Zhu J, *Xavier D*, Liu L, *Pais P*, López-Jaramillo P, Leiter LA, et al., |
The New England Journal of Medicine |
2016 |
|
133 |
Global, regional, and national Incidence, prevalence, and years lived with disability for 310 diseases and injuries, 1990-2015: A systematic analysis for the Global Burden of Disease Study 2015
|
Vos T, Allen C, Arora M, Cornaby L, Dandona L, *Xavier D*, et al.. |
Lancet |
2016 |
|
134 |
Non-physician health workers for improving adherence to medications and healthy lifestyle following acute coronary syndrome: 24-month follow-up study
|
KK Sharma, R Gupta, *M Mathur*, V Natani, S Lodha, S Roy, *D Xavier*. |
Indian Heart Journal |
2016 |
|
135 |
Treatments and outcomes of cardiac arrhythmias after myocardial infarction: a prospective, follow up study in a tertiary-care hospital.
|
A Pandit, K Verghese, R Rathore, *D Xavier*. |
International Education and Research Journal |
2016 |